No investigations to date have assessed the relationship between BOLD-LFOs and plasma pTau217, or how this relationship differs in apolipoprotein-e4 (APOE4) carriers who are vulnerable to cerebrovascular dysfunction and predisposed to AD pathophysiology. Here, APOE is linked to Alzheimer disease.